CoChat

Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions

Open access
Basner-Tschakarjan, Etiena, Mingozzi, Federico · 2014 · Frontiers in Immunology
Cited by 95

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Adeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to some of the most exciting results in the field of gene therapy and, recently, to the market approval of an AAV-based drug in Europe. With clinical development, however, it became obvious that the host immune system represents an important obstacle to successful gene transfer with AAV vectors. In this review article, we will discuss the issue of cytotoxic T cell responses directed against the AAV capsid encountered on human studies. While over the past several years the field has acquired a tremendous amount of information on the interactions of AAV vectors with the immune system, a lot of questions are still unanswered. Novel concepts are emerging, such as the relationship between the total capsid dose and the T cell-mediated clearance of transduced cells, the potential role of innate immunity in vector immunogenicity highlighted in preclinical studies, and the cross talk between regulatory and effector T cells in the determination of the outcome of gene transfer. There is still a lot to learn about immune responses in AAV gene transfer, for example, it is not well understood what are the determinants of the kinetics of activation of T cells in response to vector administration, why not all subjects develop detrimental T cell responses following gene transfer, and whether the intervention strategies currently in use to block T cell-mediated clearance of transduced cells will be safe and effective for all gene therapy indications. Results from novel preclinical models and clinical studies will help to address these points and to reach the important goal of developing safe and effective gene therapy protocols to treat human diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2014.00350

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 54

  1. Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 1233158, 10.1126/science.1233158 · DOI · Paper page
  2. Cideciyan, 2008, Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics, Proc Natl Acad Sci U S A, 105, 15112, 10.1073/pnas.0807027105 · DOI · Paper page
  3. Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI · Paper page
  4. Naldini, 2011, Ex vivo gene transfer and correction for cell-based therapies, Nat Rev Genet, 12, 301, 10.1038/nrg2985 · DOI · Paper page
  5. Buning, 2013, Gene therapy enters the pharma market: the short story of a long journey, EMBO Mol Med, 5, 1, 10.1002/emmm.201202291 · DOI · Paper page
  6. Li, 2007, Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo, J Virol, 81, 7540, 10.1128/JVI.00529-07 · DOI · Paper page
  7. Li, 2007, Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes, Mol Ther, 15, 792, 10.1038/mt.sj.6300090 · doi:10.1038/mt.sj.6300090
  8. Martino, 2013, Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells, Blood, 121, 2224, 10.1182/blood-2012-10-460733 · DOI · Paper page
  9. Muzyczka, 2001, Parvoviridae: The Viruses and Their Replication
  10. Sonntag, 2010, A viral assembly factor promotes AAV2 capsid formation in the nucleolus, Proc Natl Acad Sci U S A, 107, 10220, 10.1073/pnas.1001673107 · DOI · Paper page
  11. Zhou, 1998, In vitro packaging of adeno-associated virus DNA, J Virol, 72, 3241, 10.1128/JVI.72.4.3241-3247.1998 · DOI · Paper page
  12. Atchison, 1965, Adenovirus-associated defective virus particles, Science, 149, 754, 10.1126/science.149.3685.754 · DOI · Paper page
  13. Arechavaleta-Velasco, 2008, Adverse reproductive outcomes in urban women with adeno-associated virus-2 infections in early pregnancy, Hum Reprod, 23, 29, 10.1093/humrep/dem360 · DOI
  14. Rogers, 2011, Innate immune responses to AAV Vectors, Front Microbiol, 2, 194, 10.3389/fmicb.2011.00194 · DOI · Paper page
  15. Zwart, 2009, An experimental test of the independent action hypothesis in virus-insect pathosystems, Proc Biol Sci, 276, 2233, 10.1098/rspb.2009.0064 · DOI
  16. Martino, 2011, The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver, Blood, 117, 6459, 10.1182/blood-2010-10-314518 · DOI · Paper page
  17. Buchlis, 2012, Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer, Blood, 119, 3038, 10.1182/blood-2011-09-382317 · DOI · Paper page
  18. Niemeyer, 2009, Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood, 113, 797, 10.1182/blood-2008-10-181479 · DOI · Paper page
  19. Wang, 2005, Major role of local immune responses in antibody formation to factor IX in AAV gene transfer, Gene Ther, 12, 1453, 10.1038/sj.gt.3302539 · DOI
  20. Arruda, 2010, Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B, Blood, 115, 4678, 10.1182/blood-2009-12-261156 · DOI · Paper page
  21. Haurigot, 2010, Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs, Mol Ther, 18, 1318, 10.1038/mt.2010.73 · DOI · Paper page
  22. Toromanoff, 2010, Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle, Mol Ther, 18, 151, 10.1038/mt.2009.251 · DOI · Paper page
  23. Sun, 2007, Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance, Am J Hum Genet, 81, 1042, 10.1086/522236 · DOI
  24. Annoni, 2013, Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice, EMBO Mol Med, 5, 1684, 10.1002/emmm.201302857 · DOI · Paper page
  25. Cao, 2007, Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer, Blood, 110, 1132, 10.1182/blood-2007-02-073304 · DOI · Paper page
  26. Martino, 2009, Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity, PLoS One, 4, e6376, 10.1371/journal.pone.0006376 · DOI · Paper page
  27. Follenzi, 2004, Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice, Blood, 103, 3700, 10.1182/blood-2003-09-3217 · DOI · Paper page
  28. Breous, 2011, Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver, Gastroenterology, 141, 348, 10.1053/j.gastro.2011.04.002 · DOI · Paper page
  29. Matzinger, 2002, The danger model: a renewed sense of self, Science, 296, 301, 10.1126/science.1071059 · DOI · Paper page
  30. He, 2013, Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical, Hum Gene Ther, 24, 545, 10.1089/hum.2013.065 · DOI · Paper page
  31. Oliveira, 2013, Importance of TAP-independent processing pathways, Mol Immunol, 55, 113, 10.1016/j.molimm.2012.10.005 · DOI
  32. Li, 2012, Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther, 19, 288, 10.1038/gt.2011.90 · DOI · Paper page
  33. Erles, 1999, Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV), J Med Virol, 59, 406, 10.1002/(SICI)1096-9071(199911)59:3406::AID-JMV223.0.CO;2-N · doi:10.1002/(sici)1096-9071(199911)59:3406::aid-jmv223.0.co;2-n
  34. Hui, 2012, Characterization of AAV T cell epitopes presented by splenocytes from normal human donors, Mol Ther ASGCT Annu Meet Abstr, 20, S557
  35. Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci U S A, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
  36. Basner-Tschakarjan, 2013, Cellular immune responses to vector in a gene therapy trial for hemophilia b using an AAV8 self-complementary factor IX vector, Blood Am Soc Hematol Annu Meet, 122, 21
  37. Flotte, 2005, Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy, Hum Gene Ther, 16, 921, 10.1089/hum.2005.16.921 · DOI · Paper page
  38. Herson, 2012, A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Brain, 135, 483, 10.1093/brain/awr342 · DOI · Paper page
  39. Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann Neurol, 66, 290, 10.1002/ana.21732 · DOI · Paper page
  40. Ozeri, 2012, Alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells, J Immunol, 189, 146, 10.4049/jimmunol.1101340 · DOI
  41. Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial, Lancet Neurol, 9, 1164, 10.1016/S1474-4422(10)70254-4 · DOI · Paper page
  42. Finn, 2012, The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy, Blood, 120, 4521, 10.1182/blood-2012-06-440123 · DOI · Paper page
  43. Siner, 2013, Minimal modification in the factor VIII B domain sequence ameliorates the murine hemophilia A phenotype, Blood, 121, 4396, 10.1182/blood-2012-10-464164 · DOI · Paper page
  44. Nair, 2014, Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy, Blood, 123, 3195, 10.1182/blood-2013-10-534032 · DOI · Paper page
  45. Ward, 2011, Codon optimization of human factor VIII cDNAs leads to high-level expression, Blood, 117, 798, 10.1182/blood-2010-05-282707 · DOI · Paper page
  46. Alé, 2014, Neurotoxicity induced by antineoplastic proteasome inhibitors, Neurotoxicology, 10.1016/j.neuro.2014.02.001 · DOI
  47. Wang, 2012, Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies, Mol Ther, 20, 1501, 10.1038/mt.2012.111 · DOI · Paper page
  48. Finn, 2010, Rabbit anti-thymocyte globulin (rATG) administrated concomitantly with liver delivery of AAV2-hFIX can promote inhibitor formation in rhesus macaques, Blood, 116, 3765, 10.1182/blood.V116.21.3765.3765 · DOI
  49. De Groot, 2008, Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”, Blood, 112, 3303, 10.1182/blood-2008-02-138073 · DOI · Paper page
  50. Hui, 2013, Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes, Mol Ther, 21, 1727, 10.1038/mt.2013.166 · DOI · Paper page
  51. Cousens, 2013, Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes, J Diabetes Res, 2013, 621693, 10.1155/2013/621693 · DOI
  52. van der Marel, 2012, Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis, World J Gastroenterol, 18, 4288, 10.3748/wjg.v18.i32.4288 · DOI
  53. Britten, 2011, Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond, Cancer Immunol Immunother, 60, 15, 10.1007/s00262-010-0940-z · DOI
  54. Britten, 2013, Immunological monitoring to rationally guide AAV gene therapy, Front Immunol, 4, 273, 10.3389/fimmu.2013.00273 · DOI

Cited by

See all 95

Metadata

Authors
Basner-Tschakarjan, E., & Mingozzi, F.
Venue
Frontiers in Immunology
Published
2014-07-23
Volume
5
Pages
350-350
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2053755635
Cited by
95
References
68
FWCI
5.55
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. https://app.cochat.ai/papers/10.3389/fimmu.2014.00350
The paper
Basner-Tschakarjan, E., & Mingozzi, F. (2014). Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2014.00350

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.